Profit Before Tax (PBT) before exceptional item grew 24.7% yoy to Rs65.3cr from Rs52.3cr. Profit After Tax declined 12.3% yoy to Rs51.6cr compared to Rs58.9cr. PAT margin declined 279bps to 10.3%. EPS declined 12.3% to 5.54 from 6.32
Consolidated PAT for FY21 grew 98.3% yoy to Rs280.4cr. PAT Margin (%) expanded to 13.0%. Revenue for FY21 stood at Rs2,159.3cr, higher by 19.5% yoy compared to 1,807.6cr in FY20 on account of volume growth and secular revenue growth across all business segments.
EBITDA grew 67.7% yoy to Rs441.6cr. EBITDA Margin (%) expanded to 20.5%. EBITDA and EBITDA Margins improved significantly on account of robust volume growth, operational efficiency and operating leverage, better realisations in API segment.
Finance cost came down by 31.9% yoy to Rs23.0cr. This has resulted into improved return ratios and profitability. Comfortable Leverage Position: Debt-Equity Ratio as on March 21 was 0.38x on a consolidated basis due to strong internal accruals. This puts the Company in a good position for raising long term debt in addition to strong internal accruals to finance upcoming projects.
Commenting on the results Adhish Patil, Chief Financial Officer – Aarti Drugs Limited said, “We are delighted with the financial and operational performance across all our segments and geographies during the year. Operating leverage, process improvement initiatives and product launches across portfolios helped us to deliver a record high profit. We are very confident in strengthening our performance further in FY 2022 and beyond.
The API segment registered a growth of 8.7% in Q4 yoy basis on the back of strong volume growth. On a full year basis, the API segment delivered a growth of 18.3%, which was driven by a strong volume growth, better realisations and improved product mix.”